Background
Methods
Immunohistochemical staining
Analysis of immunohistochemistry results
Statistical analysis
Results
VEGFR-2, PDGFR-β, c-MET
Expression of VEGFR-2, PDGFR-β, and c-MET in the tissues of HCC patients
VEGFR-2, PDGFR-β, c-MET
Relationships between expression of VEGFR-2, PDGFR-β, and c-Met and clinicopathological factors
Parameters | N | VEGFR-2 | P | PDGFR-β | P | C-MET | P | |||
---|---|---|---|---|---|---|---|---|---|---|
High | Low | High | Low | High | Low | |||||
N(%) | 93 | 80(86.0) | 13 | 18(19.4) | 75 | 75(80.6) | 18 | |||
Gender
| ||||||||||
Male | 77 | 69(89.6) | 8 | 15(19.5) | 62 | 61(79.2) | 16 | |||
Female | 16 | 11(68.8) | 5 | 0.044 | 3(18.8) | 13 | 0.627 | 14(87.5) | 2 | 0.355 |
Age
| ||||||||||
≤50 | 31 | 26(83.9) | 5 | 6(19.4) | 25 | 25(80.6) | 6 | |||
>50 | 62 | 54(87.1) | 8 | 0.448 | 12(19.4) | 50 | 0.602 | 50(80.6) | 12 | 0.616 |
HBsAg
| ||||||||||
Positive | 79 | 71(89.9) | 8 | 16(20.3) | 63 | 63(79.7) | 16 | |||
Negative | 14 | 9(64.3) | 5 | 0.024 | 2(14.3) | 12 | 0.461 | 12(85.7) | 2 | 0.461 |
AFP(IU/ML) | ||||||||||
≤400 | 47 | 39(83.0) | 8 | 5(10.6) | 42 | 39(83.0) | 8 | |||
>400 | 46 | 41(89.1) | 5 | 0.290 | 13(28.3) | 33 | 0.029 | 36(78.3) | 10 | 0.377 |
Tumor number
| ||||||||||
Single | 29 | 26(89.7) | 3 | 2(6.9) | 27 | 23(79.3) | 6 | |||
>1 | 64 | 54(84.4) | 10 | 0.371 | 16(25.0) | 48 | 0.033 | 52(81.3) | 12 | 0.516 |
Tumor size(cm) | ||||||||||
≤5 | 16 | 13(81.3) | 3 | 4(25.0) | 12 | 13(81.3) | 3 | |||
>5 | 77 | 67(87.0) | 10 | 0.394 | 14(18.2) | 63 | 0.373 | 62(80.5) | 15 | 0.627 |
Differentiation | ||||||||||
High | 26 | 26(100) | 0 | 7(26.9) | 19 | 21(80.8) | 5 | |||
Middle | 45 | 38(84.4) | 7 | 6(13.3) | 39 | 35(77.8) | 10 | |||
Low | 22 | 16(72.7) | 6 | 0.023 | 5(22.7) | 17 | 0.340 | 19(86.4) | 3 | 0.705 |
Child-Pugh | ||||||||||
A | 82 | 70(85.4) | 12 | 14(17.1) | 68 | 64(78.0) | 18 | |||
B | 11 | 10(90.9) | 1 | 0.523 | 4(36.4) | 7 | 0.134 | 11(100) | 0 | 0.080 |
BCLC
| ||||||||||
B | 20 | 15(75.0) | 5 | 2(10.0) | 18 | 13(65.0) | 7 | |||
C | 73 | 65(89.0) | 8 | 0.111 | 16(21.9) | 57 | 0.194 | 62(84.9) | 11 | 0.051 |
Hepatic cirrhosis
| ||||||||||
Yes | 48 | 45(93.8) | 3 | 5(10.4) | 43 | 37(77.1) | 11 | |||
No | 45 | 35(77.8) | 10 | 0.026 | 13(28.9) | 32 | 0.023 | 38(84.4) | 7 | 0.263 |
Ascites | ||||||||||
Yes | 19 | 17(89.5) | 2 | 3(15.8) | 16 | 17(89.5) | 2 | |||
No | 74 | 63(85.1) | 11 | 0.476 | 15(20.3) | 59 | 0.470 | 58(78.4) | 16 | 0.228 |
Tumor thrombus | ||||||||||
Yes | 38 | 33(86.8) | 5 | 10(26.3) | 28 | 34(89.5) | 4 | |||
No | 55 | 47(85.5) | 8 | 0.551 | 8(14.5) | 47( | 0.126 | 41(74.5) | 14 | 0.061 |
Extrahepatic metastasis
| ||||||||||
Yes | 48 | 43(89.6) | 5 | 8(16.7) | 40 | 40(83.3) | 8 | |||
No | 45 | 37(82.2) | 8 | 0.235 | 10(22.2) | 35 | 0.339 | 35(77.8) | 10 | 0.339 |
HCC
Relationships between clinicopathological factors and prognosis
Parameters | N | PFS | OS | |||||
---|---|---|---|---|---|---|---|---|
Months |
χ
2
| P | Months |
χ
2
| P | |||
Gender
| Male | 55 | 4.433 | 7.400 | ||||
Female | 10 | 6.200 | 0.609 | 0.435 | 10.200 | 0.340 | 0.560 | |
Age
| ≤50 | 22 | 4.000 | 5.867 | ||||
>50 | 43 | 5.833 | 3.934 | 0.047 | 8.067 | 0.113 | 0.736 | |
HBsAg
| Positive | 55 | 4.433 | 6.467 | ||||
Negative | 10 | 5.833 | 0.516 | 0.472 | 8.800 | 3.608 | 0.057 | |
AFP(IU/ml) | ≤400 | 31 | 7.000 | 11.133 | ||||
>400 | 34 | 4.233 | 3.016 | 0.082 | 5.200 | 5.236 | 0.022 | |
Tumor number
| Single | 18 | 5.600 | 8.967 | ||||
>1 | 47 | 4.967 | 0.168 | 0.682 | 5.867 | 0.981 | 0.322 | |
Tumor size(cm) | ≤5 | 12 | 7.300 | 29.267 | ||||
>5 | 53 | 4.367 | 3.792 | 0.051 | 5.867 | 9.834 | 0.002 | |
Differentiation | High | 17 | 6.200 | 5.233 | ||||
Middle | 33 | 4.367 | 8.967 | |||||
Low | 15 | 4.000 | 3.630 | 0.163 | 5.667 | 3.097 | 0.213 | |
Child-Pugh | A | 59 | 5.600 | 8.067 | ||||
B | 6 | 4.967 | 0.599 | 0.439 | 3.600 | 1.980 | 0.159 | |
BCLC
| B | 7 | 5.633 | 10.500 | ||||
C | 58 | 4.433 | 3.527 | 0.060 | 7.400 | 0.274 | 0.600 | |
Hepatic cirrhosis
| Yes | 34 | 4.967 | 6.533 | ||||
No | 31 | 4.433 | 0.002 | 0.965 | 8.967 | 0.194 | 0.659 | |
Ascites | Yes | 14 | 4.367 | 5.000 | ||||
No | 51 | 5.600 | 2.706 | 0.100 | 8.967 | 3.887 | 0.049 | |
Tumor thrombus | Yes | 28 | 3.000 | 5.000 | ||||
No | 37 | 5.833 | 2.800 | 0.094 | 11.367 | 8.067 | 0.005 | |
Extrahepatic metastasis
| Yes | 41 | 4.367 | 6.467 | ||||
No | 24 | 5.600 | 0.878 | 0.349 | 8.967 | 0.017 | 0.897 |
VEGFR-2, PDGFR-β, c-MET
Relationships between expression of VEGFR-2, PDGFR-β, and c-MET and prognosis in patients who took sorafenib
N | PFS OS | ||||||
---|---|---|---|---|---|---|---|
Months |
χ
2
| P | months |
χ
2
| P | ||
PDGFR-β | 65 | ||||||
High | 13 | 4.23 | 5.87 | ||||
Low | 52 | 5.60 | 1.345 | 0.246 | 8.97 | 3.996 | 0.046 |
VEGFR-2 | 65 | ||||||
High | 58 | 4.97 | 7.40 | ||||
Low | 7 | 7.93 | 0.391 | 0.532 | 11.37 | 0.514 | 0.473 |
c-MET | 65 | ||||||
High | 55 | 5.60 | 8.97 | ||||
Low | 10 | 1.43 | 6.558 | 0.010 | 6.47 | 0.930 | 0.335 |